Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio

Kokubun, Masae; Imafuku, Yuji; Okada, Minoru; Ohguchi, Yoshito; Ashikawa, Tatsuhiko; Yamada, Toshiyuki; Yoshida, Hiroshi

doi:10.1016/j.cccn.2005.04.006

Cited by 20 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of SAA in blood is elevated in response to trauma, infection, inflammation and other acute-phase responses [13][14][15] . It was also reported previously that the elevation of SAA was detected in many types of tumors [16][17][18] , including lung cancer [7] .…”

Section: Discussionmentioning

confidence: 99%

“…SAA is an acute phase reactant, synthesized mainly in liver, whose level in the serum is elevated in head and neck cancer, renal carcinoma, ovarian cancer. SAA was also reported as biomarkers of some diseases and tumors [5,6] . The level of SAA measured by ELISA was reportedly increased in lung cancer patients, while the small number of samples (25) and lack of the detailed clinical stages analysis in those patients were less satisfied in their studies [7] .…”

mentioning

confidence: 99%

“…This technology proclaims its advantages especially in raw mixture samples, since it can analyze those samples directly, such as serum, urine, tears and so forth. An increasing number of cancer-related biomarkers for diagnosis, progression and prognosis have been successfully identified by SELDI technique [3][4][5][6] . SAA is an acute phase reactant, synthesized mainly in liver, whose level in the serum is elevated in head and neck cancer, renal carcinoma, ovarian cancer.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum

et al. 2007

View full text Add to dashboard Cite

Two hundred and eighteen serum samples from 175 lung cancer patients and 43 healthy individuals were analyzed by using Surface Enhaced Laser Desorption/Ionization Time of Flight Mass Spectrome-try (SELDI-TOF-MS). The data analyzed by both Biomarker Wizardtrade mark and Biomarker Patternstrade mark software showed that a protein peak with the molecular weight of 11.6 kDa significantly increased in lung cancer. Meanwhile, the level of this biomarker was progressively increased with the clinical stages of lung cancer. The candidate biomarker was then obtained from tricine one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis by matching the molecular weight with peaks on WCX2 chips and was identified as Serum Amyloid A protein (SAA) by MALDI/MS-MS and database searching. It was further validated in the same serum samples by immunoprecipitation with commercial SAA antibody. To confirm the SAA differential expression in lung cancer patients, the same set of serum samples was measured by ELISA assay. The result showed that at the cutoff point 0.446 (OD value) on the Receiver Operating Characteristic (ROC) curve, SAA could better discriminate lung cancer from healthy individuals with sensitivity of 84.1% and specificity of 80%. These findings demonstrated that SAA could be characterized as a biomarker related to pathological stages of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum

et al. 2007

View full text Add to dashboard Cite

show abstract

“…SAA is an acute-phase reactant, whose level in blood is elevated in response to trauma, infection, inflammation and neoplasia (18)(19)(20). However, SAA is considered to be an acutephase protein existing as various isoforms at a molecular mass of 11.1-11.9 kDa.…”

Section: Discussionmentioning

confidence: 99%

Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling

et al. 2012

View full text Add to dashboard Cite

Abstract. The purpose of this study was to screen serum samples from gastric carcinoma patients and to determine whether serum amyloid A protein (SAA) served as a biomarker. SELDI technology was used to screen for changes in SAA levels in the serum samples. A mass cluster with a mass/ charge (m/z) value between 11.1 and 11.9 kDa was identified in the serum samples from gastric carcinoma patients which was much higher than that of the control group. Furthermore, the increase in this m/z peak correlated with the severity of the cancer. High-performance liquid chromatography (HPLC) analysis confirmed that the peak was SAA1. In conclusion, this increase in SAA may be used as a potential biomarker for gastric cancer.

show abstract

“…128 One study reported that SAA is an inducer of MMPs in the synovial tissue fibroblasts of RA patients. 129 Therefore, SAA may play a significant role in the degradation of extracellular matrix in joint tissues of RA patients.…”

Section: Serum Amyloid-associated Proteinmentioning

confidence: 99%

Biomarkers of outcome in rheumatoid arthritis

Carrasco

Barton

2010

Rheumatol Rep

View full text Add to dashboard Cite

show abstract

Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio

Cited by 20 publications

References 21 publications

Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum

Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum

Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling

Biomarkers of outcome in rheumatoid arthritis

Contact Info

Product

Resources

About